Author

B. Haynes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 5 Research Focus:drug response / drug discovery· 3 Research Focus:benchmarking· 2 Organism:human· 1 Assay:proteomics· 1 Research Focus:variant calling· 1

Frequent Co-Authors

R. S. Baric· 4 shared A. Schaefer· 3 shared D. Li· 3 shared D. Martinez· 3 shared K. O. Saunders· 3 shared M. Barr· 3 shared R. Parks· 3 shared B. Yount· 2 shared

Activity by Year

2021-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

R. S. Baric

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice

D. Martinez, A. R. Schaefer, T. Gavitt, M. Mallory, E. Lee, N. Catanzaro, H. Chen, K. Gully, T. D. Scobey, P. Korategere, A. Brown, L. Smith, R. Parks, M. Barr, A. Newman, , K. O. Saunders

This study develops a trivalent RBD nanoparticle vaccine that protects mice against both merbecovirus and sarbecovirus challenges, including SARS-CoV, MERS-CoV, and SARS-CoV-2.

Cell Reports · Oct 1, 2023Peer-reviewedImmunology

Expression of extracellular Hsp90 is a molecular signature of T cell activation, providing a means to image and target T Cell activation in autoimmune disease

S. Scarneo, A. Smith, J. Favret, R. O'connell, J. Pickeral, K. Yang, G. Ferrari, D. Loiselle, P. Hughes, M. Kulkarni, M. Gargesha, B. Scott, D. Roy, B. Haynes, J. Kweik, T. Haystead

This study identifies eHsp90 as a marker of T cell activation, showing its upregulation in autoimmune diseases and demonstrating the efficacy of an inhibitor in delaying disease progression.

bioRxiv · Jun 6, 2021 · PreprintPharmacology & Toxicology

A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

D. Martinez, A. Schaefer, S. Gobeil, D. Li, G. De la Cruz, R. Parks, X. Lu, M. Barr, K. Manne, K. Mansouri, R. J. Edwards, B. Yount, K. Anasti, S. Montgomery, X. Shen, , R. S. Baric

A broadly neutralizing antibody protects against multiple SARS-CoV and SARS-CoV-2 variants in mice by targeting a conserved epitope in the receptor-binding domain.

bioRxiv · Apr 27, 2021 · PreprintMicrobiology

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

D. R. Martinez, A. Schaefer, S. R. Leist, G. De la Cruz, A. West, E. N. Atochina-Vasserman, L. C. Lindesmith, N. Pardi, R. Parks, M. Barr, D. Li, B. Yount, K. O. Saunders, D. Weissman, B. Haynes, , R. S. Baric

This study shows chimeric spike mRNA vaccines protect mice against multiple Sarbecovirus strains, including variants and zoonotic viruses, better than standard SARS-CoV-2 vaccines.

bioRxiv · Mar 11, 2021Microbiology

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

D. Martinez, A. Schaefer, S. R. Leist, D. Li, K. Gully, J. Feng, E. Bunyan, D. Porter, T. Cihlar, S. Montgomery, B. Haynes, R. S. Baric, M. C. Nussenzweig, T. P. Sheahan

This study evaluates combination therapies of remdesivir and monoclonal antibodies for SARS-CoV-2 and its B.1.351 variant in mice, showing improved outcomes with the antibody combination.

bioRxiv · Jan 27, 2021Microbiology